Nisa Investment Advisors
ELVN icon

Nisa Investment Advisors’s Enliven Therapeutics ELVN Stock Holding History

Nisa Investment Advisors’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$40.9K Buy
1,044
+455
+77% +$12.6K ﹤0.01% 1753
2025
Q4 		$9.07K Sell
589
-27
-4% -$538 ﹤0.01% 2267
2025
Q3 		$12.6K Sell
616
-89
-13% -$1.79K ﹤0.01% 2194
2025
Q2 		$14.1K Buy
705
+23
+3% +$435 ﹤0.01% 2100
2025
Q1 		$13.4K Sell
682
-11
-2% -$237 ﹤0.01% 2020
2024
Q4 		$15.6K Buy
693
+31
+5% +$804 ﹤0.01% 2016
2024
Q3 		$16.9K Buy
662
+607
+1,104% +$14.1K ﹤0.01% 1962
2024
Q2 		$1.28K Buy
55
+40
+267% +$842 ﹤0.01% 2463
2024
Q1 		$264 Buy
15
+6
+67% +$92 ﹤0.01% 2604
2023
Q4 		$125 Hold
9
– – ﹤0.01% 2602
2023
Q3 		$123 Sell
9
-7
-44% -$118 ﹤0.01% 2715
2023
Q2 		$327 Buy
+16
New +$323 ﹤0.01% 2644

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nisa Investment Advisors's ELVN Position: Q1 2026 in Review

Nisa Investment Advisors increased its Enliven Therapeutics (ELVN) stake by 77% in Q1 2026, buying an estimated $12.6K and bringing the position to 1,044 shares worth $40.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1753.

Nisa Investment Advisors first reported a position in ELVN in Q2 2023 and has held it in 12 quarters since. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Nisa Investment Advisors held 1,044 shares of Enliven Therapeutics worth $40.9K as of Q1 2026.
  • Nisa Investment Advisors bought 455 Enliven Therapeutics shares in Q1 2026, an estimated $12.6K.
  • Enliven Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q1 2026, its #1753 holding.
  • Nisa Investment Advisors first reported a position in Enliven Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.